Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay
- 1 October 2016
- journal article
- Published by Elsevier BV in Clinical Biochemistry
- Vol. 49 (15), 1202-1204
- https://doi.org/10.1016/j.clinbiochem.2016.07.016
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Monoclonal Antibodies in Multiple Myeloma Come of AgeNew England Journal of Medicine, 2015
- Targeting CD38 with Daratumumab Monotherapy in Multiple MyelomaNew England Journal of Medicine, 2015
- Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapyLeukemia, 2015
- Current treatment landscape for relapsed and/or refractory multiple myelomaNature Reviews Clinical Oncology, 2014
- Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Blood, 2011
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1Blood, 2011
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disordersLeukemia, 2008
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myelomaBlood, 2008
- Detection by Immunofixation of M Proteins in Hypogammaglobulinemic Patients With Normal Serum Protein Electrophoresis ResultsAmerican Journal of Clinical Pathology, 2007